
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is advancing its clinical-stage oncology pipeline, particularly with its promising drug BDTX-1535, which has shown an overall response rate (ORR) of 36% in patients with difficult-to-treat non-small cell lung cancer (NSCLC) harboring specific mutations. The improvement in ORR to 42% when excluding patients without on-target resistance mutations highlights the targeted efficacy of this therapy, suggesting significant therapeutic potential against current market options. Additionally, the company's focus on the unmet need in first-line treatment of non-classical EGFR mutations positions it favorably for future growth, especially with data updates anticipated in 2025 that may further validate its approach.
Bears say
Black Diamond Therapeutics Inc faces significant risks that negatively impact its stock outlook, including potential negative efficacy or safety data for its leading pipeline candidate BDTX-1535, as well as the possibility of disappointing results from other pipeline candidates. The company's recent adjustments to near- to mid-term expense assumptions and commercialization timelines, compounded by a forecasted full-year 2025 net loss of $1.32 per share, indicate reduced financial stability. Additionally, there is concern regarding the risk of long-term dilution, which could further diminish shareholder value.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares